BIAsp 30

DRUG3 trials

Sponsors

Tehran University of Medical Sciences, Novo Nordisk A/S

Conditions

DiabetesDiabetes Mellitus, Type 2Diabetes Type 2

Phase 4

Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients

CompletedNCT01889095

Tehran University of Medical SciencesDiabetes Type 2

Start: 2011-07-31End: 2012-07-31Updated: 2013-06-28

Unknown Phase

A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)

CompletedNCT03374774

Novo Nordisk A/SDiabetes, Diabetes Mellitus, Type 2

Start: 2017-11-13End: 2018-07-04Updated: 2018-08-31

A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria

WithdrawnNCT03862690

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2020-05-28End: 2021-06-28Updated: 2020-07-20

Related Papers

Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market

PharmacoEconomics - Open2021-01-065 citations

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.

2016-06-097 citations